Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

BlueBird Bio (Cambridge, MA) a clinical-stage developer of innovative stem cell-based gene therapies for severe genetic disorders, closed a $30M Series C financing. Participants include Arch Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group.

Ceregene (San Diego, CA) a clinical-stage biopharmaceutical company focused adeno-associated virus vector-based gene therapy for Parkinson’s and Alzheimer’s disease, closed a $11.5M Series D financing. Participants include Hamilton BioVentures, Alta Partners, MPM Capital and Investor Growth Capital.

Genetix Pharmaceuticals (Cambridge, MA) a clinical-stage gene therapy company whose lentiviral technology is focused upon severe genetic disorders such as adrenoleukodystrophy and beta-thalassemia, closed a $35M Series B financijng. Participants include Third Rock Ventures, Genzyme Ventures, TVM Capital, Forbion and Easton Capital.

Celladon (La Jolla, CA) a clinical-stage company focused on gene therapy for congestive heart failure, closed a $21.8M Series C financing. Participants include Enterprise Partners Venture Capital, Venrock and Johnson & Johnson Dev Corp.


to top of page...